We then tested if targeting specifically muscle DNM2 through removal of exon 12b is efficient to rescue the CNM hallmarks of the Mtm1−/y mouse, a faithful model of XLCNM, to increase the specificity of this therapy towards the muscle tissue. This evidence concerns the gene DNM2 and X-linked myotubular myopathy.